Ana Fernández Montés

Author

Also Known As

A Montes, A Ramchandani, A. Díaz-Serrano, A. F. Montes, A. Fernandez Montes, A. Fernández Montes, A. Fernández-Montes, A. MONTES, A. Montes, A. Montes Oca

289

Publications

3.5K

Citations

H-Index

Concepts

All Affiliations

Complejo Hospitalario de Ourense Hospital Universitario Central de Asturias Complexo Hospitalario Universitario A Coruña Hospital Universitario La Paz Hospital General Universitario de Elche

About

Ana Fernández Montés is an author at Complejo Hospitalario de Ourense specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	19	747
2	Health Sciences	5	5	88
3	Education	1	1	41
4	Cell Biology	1	1	111
5	Endocrinology	1	1	11

Ana Fernández Montés

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer Manuel Cobo, Dolores Isla, Bartomeu Massutí, Journal of Clinical Oncology	2007	442
Copy number signatures and mutational processes in ovarian carcinoma Geoff Macintyre, Teodora Goranova, Dilrini De Silva, Nature Genetics Somatic VariantTumor HeterogeneityPathologyOvarian CancerCopy Number Signatures	2018	433
A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors Rebecca Kristeleit, Geoffrey I. Shapiro, Howard A. Burris, Clinical Cancer Research	2017	236
A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) Luis Paz‐Ares, J. M. Sanchez, A. García, Journal of Clinical Oncology Advanced NsclcMedicineTyrosine KinasePharmacologyHigh Response Rate	2006	162
Snai1 and Snai2 collaborate on tumor growth and metastasis properties of mouse skin carcinoma cell lines David Olmeda, Ana Fernández Montés, Gema Moreno‐Bueno, Oncogene Oncogenic AgentMedicineTumor GrowthMetastasis PropertiesTumor Suppressor	2008	111
Lung fibrotic tenascin-C upregulation is associated with other extracellular matrix proteins and induced by TGFβ1 Susanna Estany, Vanesa Vicens‐Zygmunt, Roger Llatjós, BMC Pulmonary Medicine	2014	102
Copy-number signatures and mutational processes in ovarian carcinoma Geoff Macintyre, Teodora Goranova, Dilrini De Silva, OncologySomatic VariantTumor HeterogeneityCopy-number SignaturesGenetics	2017	94
Breast cancer patient experiences through a journey map: A qualitative study Laura Ciria‐Suarez, Paula Jiménez‐Fonseca, María Palacín-Lois, PLoS ONE	2021	73
Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study Alberto Carmona‐Bayonas, Paula Jiménez‐Fonseca, Ángela Lamarca, Journal of Clinical Oncology	2019	69
Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry Alberto Carmona‐Bayonas, Paula Jiménez‐Fonseca, Isabel Echavarría, European Journal of Surgical Oncology Surgical OncologyEsophagusEsophageal CancerAgamenon National RegistryGastrointestinal Oncology	2018	59

Page 1